• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    BetterInvesting™ Magazine Update on Merck (MRK) and Ball (BALL)

    10/25/24 4:15:00 PM ET
    $BALL
    $MRK
    Containers/Packaging
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BALL alert in real time by email

    TROY, Mich., Oct. 25, 2024 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Merck & Co. (NYSE:MRK) as its "Stock to Study" and Ball Corp (NYSE:BALL) as its "Undervalued Stock" in the January 2025 issue for investors' informational and educational use.

    The organization remains concerned about the number of Americans who are investing for the future. "Too many Americans hesitate to invest, waiting for what they believe is the perfect moment, such as after the election, or for other reasons, missing out on the benefits of compounding. With Halloween less than a week away, it's a reminder that those who take part, reap the rewards," said Ken Zendel, CEO of the National Association of Investors (NAIC), the parent organization of BetterInvesting.

    To help investors get started, the National Association of Investors has launched a free eLearning course entitled Stock Investing Basics available for anyone who desires to learn at https://www.betterinvesting.org/learn-about-investing/elearning-courses

    Explore the January 2025 issue of BetterInvesting Magazine for more education as well as details about the latest stocks recommended for study by the Editorial Advisory and Securities Review Committee. Non-members can utilize the limited, trial version of the BetterInvesting online stock selection and analysis tools to study the investment potential of both Merck & Co. as well as Ball Corp. by viewing their fundamental data and applying judgments.

    Committee members are Daniel J. Boyle, CFA; Marisa Bradbury, CFA; Philip Keating, CFA; Walter J. Kirchberger, CFA; Anne Nichols, CFA; and Dan Rutter, CFA.

    As stated, the BetterInvesting committee's Stock to Study and Undervalued Stock choices are for the informational and educational uses of investors. They are not to be considered as endorsed or recommended for purchase by NAIC/BetterInvesting. BetterInvesting urges investors to educate themselves about the stock market so they can make informed decisions about stock purchases.  Investors should conduct their own review and analysis of any company of interest using the Stock Selection Guide before making an investment decision.

    About BetterInvesting:

    BetterInvesting™, a national 501(c)(3) nonprofit, investment education organization, has been empowering everyday Americans since 1951. Also known as the National Association of Investors™ (NAIC®), we have helped more than 5 million people from all walks of life learn how to improve their financial future. BetterInvesting provides unbiased, in-depth investing education and powerful online stock analysis tools to create successful lifelong investors. BetterInvesting staff, along with a dedicated community of volunteers across America, teach the organization's principles and time-tested methodology to individuals and investment clubs. For more information about BetterInvesting, please visit www.betterinvesting.org

    Follow us on LinkedIn, Instagram and Facebook.

    Contact: 877-275-6242

    Cision View original content:https://www.prnewswire.com/news-releases/betterinvesting-magazine-update-on-merck-mrk-and-ball-ball-302287661.html

    SOURCE NAIC-BetterInvesting

    Get the next $BALL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • What stock has been chosen as the 'Stock to Study' by BetterInvesting Magazine?

      Merck & Co. (NYSE: MRK) has been designated as the "Stock to Study" for investors in the upcoming January 2025 issue of BetterInvesting Magazine.

    • Which company is recognized as the 'Undervalued Stock' by BetterInvesting Magazine?

      Ball Corp (NYSE: BALL) is selected as the "Undervalued Stock" in the January 2025 issue for educational purposes.

    • What concern did Ken Zendel highlight regarding American investors?

      Ken Zendel, CEO of the National Association of Investors, expressed concern over Americans delaying investment due to perceptions of waiting for the perfect moment.

    • What initiative has the National Association of Investors launched to help beginner investors?

      The National Association of Investors has introduced a free eLearning course entitled 'Stock Investing Basics' to encourage new investors.

    • What is BetterInvesting's recommendation for investors regarding stock purchases?

      BetterInvesting advises investors to educate themselves and conduct thorough reviews before making any investment decisions.

    Recent Analyst Ratings for
    $BALL
    $MRK

    CompanyDatePrice TargetRatingAnalyst
    Merck & Company Inc.
    $MRK
    2/25/2026$142.00Outperform
    RBC Capital Mkts
    Merck & Company Inc.
    $MRK
    2/20/2026$140.00Overweight
    Barclays
    Merck & Company Inc.
    $MRK
    2/13/2026$150.00Hold → Buy
    Deutsche Bank
    Ball Corporation
    $BALL
    1/8/2026$63.00Overweight → Equal-Weight
    Morgan Stanley
    Merck & Company Inc.
    $MRK
    1/8/2026$135.00Peer Perform → Outperform
    Wolfe Research
    Ball Corporation
    $BALL
    1/6/2026$60.00Underweight → Overweight
    Wells Fargo
    Ball Corporation
    $BALL
    1/6/2026$67.00Neutral → Buy
    Citigroup
    Merck & Company Inc.
    $MRK
    12/18/2025$130.00Market Perform → Outperform
    BMO Capital Markets
    More analyst ratings

    $BALL
    $MRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on Merck with a new price target

    RBC Capital Mkts initiated coverage of Merck with a rating of Outperform and set a new price target of $142.00

    2/25/26 7:52:46 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Merck with a new price target

    Barclays initiated coverage of Merck with a rating of Overweight and set a new price target of $140.00

    2/20/26 8:25:04 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded Merck from Hold to Buy and set a new price target of $150.00

    2/13/26 8:35:09 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BALL
    $MRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by SVP, CLO & CORP SEC Lim-Johnson Hannah S.

    4 - BALL Corp (0000009389) (Issuer)

    2/23/26 5:19:14 PM ET
    $BALL
    Containers/Packaging
    Industrials

    SEC Form 4 filed by SVP & CIO Doering Edmund J.

    4 - BALL Corp (0000009389) (Issuer)

    2/23/26 5:17:42 PM ET
    $BALL
    Containers/Packaging
    Industrials

    SEC Form 4 filed by S.V.P & C.F.O Rabbitt Daniel J.

    4 - BALL Corp (0000009389) (Issuer)

    2/23/26 5:16:00 PM ET
    $BALL
    Containers/Packaging
    Industrials

    $BALL
    $MRK
    SEC Filings

    View All

    SEC Form 10-K filed by Merck & Company Inc.

    10-K - Merck & Co., Inc. (0000310158) (Filer)

    2/24/26 4:15:30 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Ball Corporation

    10-K - BALL Corp (0000009389) (Filer)

    2/19/26 12:04:56 PM ET
    $BALL
    Containers/Packaging
    Industrials

    SEC Form 13F-HR filed by Merck & Company Inc.

    13F-HR - Merck & Co., Inc. (0000310158) (Filer)

    2/17/26 4:01:41 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BALL
    $MRK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer

    KEYTRUDA plus paclitaxel with or without bevacizumab is the first PD-1 inhibitor-based regimen to show a statistically significant improvement in OS regardless of PD-L1 status Results from the final analysis of the Phase 3 KEYNOTE-B96 trial to be presented during a Best Oral Session at the European Society of Gynaecological Oncology 2026 Congress Positive EU CHMP opinion granted for KEYTRUDA plus paclitaxel with or without bevacizumab in certain adults with PD-L1 (CPS ≥1) platinum-resistant ovarian carcinoma who have received one or two prior systemic treatment regimens Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced results from the final analy

    2/27/26 10:15:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis

    The only JAK inhibitor approved in the U.S. for the control of pruritus associated with allergic dermatitis in dogs six months of age and older Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today the U.S. Food and Drug Administration (FDA) approval of NUMELVI™ (atinvicitinib tablets) – the first and only second-generation Janus kinase (JAK) inhibitor indicated for the control of pruritus associated with allergic dermatitis in dogs six months of age and older. The product is expected to be available at veterinary clinics and hospitals nationwide in spring 2026. "Merck Anima

    2/25/26 4:30:00 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026

    DOR/ISL is the first non-INSTI, two-drug regimen to demonstrate non-inferiority and a similar safety profile at Week 48 to BIC/FTC/TAF in adults living with HIV-1 who had not previously received antiretroviral treatment DOR/ISL maintained virologic suppression at Week 96 in adults with virologically suppressed HIV-1 who switched from other oral antiretroviral therapies, including BIC/FTC/TAF Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from three pivotal Phase 3 trials evaluating the investigational, once-daily, oral, two-drug regimen of doravirine/islatravir [DOR/ISL (100 mg/0.25 mg), (MK-8591A)] in adults with HIV-

    2/25/26 12:37:00 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BALL
    $MRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thulin Inge G bought $250,000 worth of shares (2,833 units at $88.25), increasing direct ownership by 2,833% to 2,933 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/7/25 4:09:51 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baker Douglas M Jr bought $1,327,500 worth of shares (15,000 units at $88.50), increasing direct ownership by 1,500% to 16,000 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/7/25 4:04:52 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP and President, EMEA Glew Mandy bought $38,367 worth of shares (563 units at $68.15) and was granted 1,148 shares, increasing direct ownership by 57% to 4,711 units (SEC Form 4)

    4 - BALL Corp (0000009389) (Issuer)

    1/30/25 5:57:00 PM ET
    $BALL
    Containers/Packaging
    Industrials

    $BALL
    $MRK
    Leadership Updates

    Live Leadership Updates

    View All

    Merck Evolves Human Health Operating Structure to Support Portfolio Execution

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today highlighted steps to evolve the structure of its Human Health organization to ensure strong commercial execution of launches across diverse therapeutic areas, positioning the company for continued commercial success. As part of this evolution, Merck is organizing its Human Health business into an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. This structure will enable Merck to sustain long-term leadership in oncology, while maintaining a sharp focus in support of a growing number of launches across an increasingly broad and diverse portfolio. In support of the new Human He

    2/23/26 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent

    CD388 is an investigational long-acting, strain-agnostic antiviral agent currently in Phase 3, designed to prevent influenza infection in individuals at higher risk of influenza complications Acquisition aligns with Merck's science-led business development strategy, diversifying and expanding the company's pipeline Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. (NASDAQ:CDTX) ("Cidara"), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per share in cash, for a tot

    11/14/25 6:45:00 AM ET
    $CDTX
    $MRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Ball Corporation Announces Board and Leadership Transitions

    Ronald J. Lewis appointed CEO, effective immediately Stuart A. Taylor II elected Chairman of the Board Daniel J. Rabbitt appointed Chief Financial Officer WESTMINSTER, Colo., Nov. 10, 2025 /PRNewswire/ -- Ball Corporation (NYSE:BALL) today announced that the Company's Board of Directors has appointed Ronald J. Lewis as Chief Executive Officer and a member of the Board of Directors, effective immediately. Lewis succeeds Daniel W. Fisher, who is stepping down from his role. The departure is not related to any disagreement with the company. Stuart A. Taylor II, Ball's Lead Independent Director, has been elected Chairman of the Board. "On behalf of the Board, I'd like to thank Dan Fisher for his

    11/10/25 9:00:00 AM ET
    $BALL
    Containers/Packaging
    Industrials

    $BALL
    $MRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ball Corporation

    SC 13G/A - BALL Corp (0000009389) (Subject)

    11/14/24 1:28:29 PM ET
    $BALL
    Containers/Packaging
    Industrials

    SEC Form SC 13G filed by Ball Corporation

    SC 13G - BALL Corp (0000009389) (Subject)

    2/14/24 10:04:34 AM ET
    $BALL
    Containers/Packaging
    Industrials

    SEC Form SC 13G/A filed by Ball Corporation (Amendment)

    SC 13G/A - BALL Corp (0000009389) (Subject)

    2/13/24 4:59:06 PM ET
    $BALL
    Containers/Packaging
    Industrials

    $BALL
    $MRK
    Financials

    Live finance-specific insights

    View All

    Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline

    Reports Strength in Oncology and Animal Health, Plus Increasing Contributions From WINREVAIR and CAPVAXIVE Fourth-Quarter Worldwide Sales Were $16.4 Billion (5% Growth; 4% Growth ex-FX) Fourth-Quarter GAAP EPS Was $1.19; Non-GAAP EPS Was $2.04; GAAP and Non-GAAP EPS Include a Charge of $0.05 per Share for the Acquisition of MK-8690 Sole Global Rights Full-Year Worldwide Sales Were $65.0 Billion (1% Growth; 2% Growth ex-FX) KEYTRUDA/KEYTRUDA QLEX Sales Were $31.7 Billion (7% Growth Both Nominally and ex-FX); Includes KEYTRUDA QLEX Sales of $40 Million WINREVAIR Sales Were $1.4 Billion CAPVAXIVE Sales Were $759 Million GARDASIL/GARDASIL 9 Sales Were $5.2 Billion (39% Decli

    2/3/26 6:30:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ball Reports Strong Fourth Quarter and Full-Year 2025 Results

    Highlights Full-year and fourth quarter U.S. GAAP diluted earnings per share of $3.30 and 75 cents, respectivelyFull-year and fourth quarter comparable diluted earnings per share of $3.57 and 91 cents, respectivelyFull-year and fourth quarter global aluminum packaging shipments up 4.1% and 6.0%, respectivelyReturned $1.54 billion to shareholders via share repurchases and dividends in 2025Generated record adjusted free cash flow of $956 million in 2025Completed acquisition of majority stake in European beverage can manufacturer BenepackIn 2026, expect comparable diluted earnings per share growth of 10-plus percent and free cash flow greater than $900 millionFocused on advancing sustainable al

    2/3/26 6:00:00 AM ET
    $BALL
    Containers/Packaging
    Industrials

    Board Declares Quarterly Dividend

    WESTMINSTER, Colo., Jan. 28, 2026 /PRNewswire/ -- Ball Corporation's (NYSE:BALL) board of directors (the "Board") today declared a cash dividend of 20 cents per share, payable March 16, 2026, to shareholders of record as of March 2, 2026. Conference Call Details Ball will announce its fourth quarter 2025 earnings on Tuesday, February 3, 2026 before trading begins on the New York Stock Exchange. At 7 a.m. Mountain Time on that day (9 a.m. Eastern Time), Ball will hold its regular quarterly conference call on the company's results and performance. Please use the following URL to join via webcast:Ball Corporation Fourth Quarter 2025 Earnings Call To participate in the live call Q&A session, Nor

    1/28/26 5:18:00 PM ET
    $BALL
    Containers/Packaging
    Industrials